Nuclear Medicine and Biology
Volume 35, Issue 6 , Pages 665-671 , August 2008

The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR

  • Feng Wang

      Affiliations

    • Department of Nuclear Medicine, Nanjing First Hospital affiliated to Nanjing Medical University, Nanjing 210006, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 25 52271491 or 13851702760; fax: +86 25 52254223.
    • These authors contributed equally to this study.
    • ,
  • Zizheng Wang

      Affiliations

    • Department of Nuclear Medicine, Nanjing First Hospital affiliated to Nanjing Medical University, Nanjing 210006, China
    • These authors contributed equally to this study.
    • ,
  • Jie Wu

      Affiliations

    • Department of Nuclear Medicine, Nanjing First Hospital affiliated to Nanjing Medical University, Nanjing 210006, China
    • ,
  • Wei Qu

      Affiliations

    • Department of Nuclear Medicine, Nanjing First Hospital affiliated to Nanjing Medical University, Nanjing 210006, China
    • ,
  • Weixuan Yao

      Affiliations

    • Department of Nuclear Medicine, Nanjing First Hospital affiliated to Nanjing Medical University, Nanjing 210006, China
    • ,
  • Jianhua Zhao

      Affiliations

    • Department of Pathology, Nanjing First Hospital affiliated to Nanjing Medical University, Nanjing 210006, China
    • ,
  • Zijun Liu

      Affiliations

    • Department of General Surgery, Nanjing First Hospital affiliated to Nanjing Medical University, Nanjing 210006, China

Received 26 January 2008 ,Revised 17 April 2008 ,Accepted 30 April 2008.

References 

  1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics CA. Cancer J Clin. 1999;49:33–64
  2. Greenlee RT, Murray T, Bolden S. Cancer statistics, 2000 CA. Cancer J Clin. 2000;50:7–33
  3. Zhang S-W, Chen W-Q, Kong L-Z, et al. An analysis of cancer incidence and mortality from 30 cancer registries in China, 1998–2002. Bull Chin Cancer. 2005;15(7):430–448
  4. Pisano ED, Fajardio LL, Caudry DJ, et al. Fine-needle aspiration biopsy of nonpalpable lesions in a multicenter clinical trial: results from the Radiologic Diagnostic Oncology Group V. Radiology. 2001;219:785–792
  5. Sauer T, Myrvold K, Lomo J, et al. Fine-needle aspiration cytology in nonpalpable mammographic abnormalities in breast cancer screening. Breast. 2003;12:314–319
  6. Jackman RJ, Burbank F, Parker SH, et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology. 2001;218:497–502
  7. Lind P, Gallowitsch H, Kogler D, et al. Tc-99m tetrofosmin mammoscintigraphy: a prospective study in primary breast lesions. Nucl Med. 1996;35:225–229
  8. Spanu A, Farris A, Schillaci O, et al. The usefulness of Tc-99m tetrofosmin scintigraphy in patients with breast cancer recurrences. Nucl Med Commun. 2003;24:145–154
  9. Flanagan F, Dehdashti F, Siegel B. PET in breast cancer. Semin Nucl Med. 1998;28:290–302
  10. Avril N, Schelling M, Dose J, Weber W, Schwaiger M. Utility of PET in breast cancer. Clin Positron Imag. 1999;2:261–271
  11. Bombardieri E, Grippa F. PET imaging in breast cancer. J Nucl Med. 2001;43:245–256
  12. Czernin J. FDG PET in breast cancer: a different view of its clinical use. Mol Imag Biol. 2002;4:35–45
  13. Heinisch M, Gallowitsch H, Mikosch P, et al. Comparison of FDG PET and dynamic contrast enhanced MRI in the evaluation of suggestive breast lesions. Breast. 2003;12:17–22
  14. Vikic-Topic S, Raisch KP, Kvols LK, et al. Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab. 1995;80:2974–2979
  15. Schulz S, Helmholz T, Schmitt J, et al. True positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of sst2A and sst5. Breast Cancer Res Treat. 2002;72:221–226
  16. Reubi JC, Waser B, Schaer JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836–846
  17. van Eijck CH, Krenning EP, Bootsma A, et al. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet. 1994;343:640–643
  18. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med. 2002;32:84–91
  19. Mezi S, Primi F, Orsi E, et al. Somatostatin Scintigraphy in the metastatic breast cancer patients. Oncol Rep 2005;13:31–35.
  20. de Jong M, Kwekkeboom D, Valkema R, et al. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging. 2003;30:463–469
  21. de Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133–140
  22. Breeman WA, Mearadji A, Capello A, et al. Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3] octreotate in a rat liver micrometastases model. Int J Cancer. 2003;104:376–379
  23. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med. 2002;43:610–616
  24. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:941–945
  25. Wang F, Wang ZZ, Yao W, et al. The role of technetium-99m sandostatin scintigraphy in suspected lung cancer compared with 18F-FDG dual head coincidense imaging. J Nucl Med. 2007;48:1442–1448
  26. Sharma K, Srikant CB. Induction of wild-type p53 Bax and acidic endonuclease during somatostatin signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer. 1998;76:259–266
  27. Papotti M, Kumar U, Volante M, et al. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol. 2001;54:641–649
  28. Van Den Bossche B, Van Belle S, De Wintery F, et al. Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy. J Nucl Med. 2006;47:6–13
  29. Pettinato C, Sarnelli A, Di Donna M, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;51:72–79
  30. Antunes P, Ginj MH, Zhang B, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur J Nucl Med Mol Imaging. 2007;34:982–993
  31. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labeling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338–1347

PII: S0969-8051(08)00107-8

doi: 10.1016/j.nucmedbio.2008.04.010

Nuclear Medicine and Biology
Volume 35, Issue 6 , Pages 665-671 , August 2008

Article Tools

* Image Usage & Resolution